去势抵抗性前列腺癌（CRPC）的难治性和高死亡率仍然是前列腺癌（PCa）领域最具挑战性的问题。新的证据表明，Wnt 信号通路是高度保守的级联，调节胚胎发育和维持组织稳态，其失调参与 PCa 发生和进展的各个阶段。本文系统地讨论了雄激素受体（AR）信号通路和Wnt信号通路参与PCa发生及其进展为CRPC的机制。具体来说，我们详细阐述了Wnt信号通路如何通过与AR通路相互作用或以不依赖AR的方式诱导前列腺细胞恶性转化，促进PCa恶性进展并建立免疫抑制性前列腺肿瘤微环境。我们还讨论了Wnt信号通路如何增强前列腺癌干细胞（PCSC）的干性特征，从而诱导CPPC的发生和转移。此外，我们还讨论了使用不同类型抑制Wnt信号通路的药物治疗PCa的最新进展。我们认为，基于 Wnt 信号传导的药物与内分泌和其他疗法的结合是必要的，并且可能会增强治疗所有类型 PCa 的临床疗效。版权所有 © 2024。由 Elsevier B.V. 出版。

The intractability and high mortality rate of castration-resistant prostate cancer (CRPC) remain the most challenging problems in the field of prostate cancer (PCa). Emerging evidence has shown that the dysregulation of Wnt signaling pathways, which are highly conserved cascades that regulate embryonic development and maintain tissue homeostasis, is involved in various stages of PCa occurrence and progression. In this review, we systemically discuss the mechanisms by which the androgen receptor (AR) signaling pathway and Wnt signaling pathways participate in the occurrence of PCa and its progression to CRPC. Specifically, we elaborate on how Wnt signaling pathways induce the malignant transformation of prostate cells, promote the malignant progression of PCa and establish an immunosuppressive prostate tumor microenvironment through interaction with the AR pathway or in an AR-independent manner. We also discuss how Wnt signaling pathways enhances the stemness characteristics of prostate cancer stem cells (PCSCs) to induce the occurrence and metastasis of CPPC. Additionally, we discuss the latest progress in the use of different types of drugs that inhibit the Wnt signaling pathways in the treatment of PCa. We believe that the combination of Wnt signaling-based drugs with endocrine and other therapies is necessary and may enhance the clinical efficacy in the treatment of all types of PCa.Copyright © 2024. Published by Elsevier B.V.